Press Release · DarioHealth Corp.
Dario CEO Erez Raphael to Lead Panel Discussion at U.S. Bancorp | BTIG Tech-Enabled Healthcare Forum
Distributed by Green Web Art · Originally issued via PR Newswire

Erez Raphael will be joined by Personify Health President Ed Liebowitz for panel discussion on the evolving digital health market, including member choice, multi-condition care, engagement and ROI
NEW YORK, Nov. 20, 2026 — DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced that Erez Raphael, the Company's Chief Executive Officer, has been invited to lead a panel discussion at the U.S. Bancorp | BTIG Tech-Enabled Healthcare Forum 2026, being held virtually on Monday, November 23, 2026.
Erez Raphael and Ed Liebowitz, President of Personify Health, a Dario channel partner, will conduct a panel discussion on the latest trends in digital health. Personify Health, a personalized health platform company that helps organizations manage risk end-to-end, is a channel partner offering Dario's high return-on-investment ("ROI") multi-condition platform to its 1,000+ active clients and 31 million lives reached. By working with channel partners such as Personify, Dario employs a one-to-many distribution model that enables the Company to efficiently add new enterprise clients at lower acquisition costs, supporting scalable growth without a proportional increase in sales and marketing investment.
U.S. Bancorp | BTIG Tech-Enabled Healthcare Forum 2026
Panel Discussion: "Chosen by Members, Funded by Payers: Delivering a Full Health Platform Ecosystem"
Panelists: Erez Raphael and Ed Liebowitz
Time: 12:00 p.m. to 12:50 p.m. EST
Topics:
- Growing member choice and its impact on how digital health solutions are purchased
- Driving sustained engagement while demonstrating measurable clinical and financial ROI
- Managing multiple chronic conditions through integrated platforms versus point solutions
- Improving outcomes and value associated with GLP-1 therapy
- Integrating navigation and clinical platforms to create a more unified member experience
For more information about the conference or to schedule a meeting with Dario's management, please contact your U.S. Bancorp | BTIG representative.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the anticipated benefits of its channel partnerships, including its partnership with Personify Health, the potential for its one-to-many distribution model to facilitate the addition of new enterprise clients, reduce customer acquisition costs and support scalable growth, and the Company's ability to expand its market reach and commercial opportunities through such partnerships. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
DarioHealth Corporate Contacts
Michael Lipari
SVP Corporate Development
[email protected]
+1-201-785-6310
Rob Halpern
SVP Marketing
[email protected]
SOURCE DarioHealth Corp.
About DarioHealth Corp.
DarioHealth (Nasdaq: DRIO) is an AI-powered healthcare technology company helping health plans, health systems and employers improve health outcomes while lowering the cost of care. The Company's integrated platform combines connected devices, personalized member engagement, AI-driven insights and provider-backed clinical care to support people living with conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health needs.
Powered by more than 13 billion proprietary longitudinal healthcare data points collected over more than a decade, Dario's AI platform personalizes care at the individual member level by analyzing biometric, clinical and behavioral data to deliver more timely and effective interventions. By combining engagement, clinical intelligence and care delivery within a single platform, Dario helps customers address multiple chronic conditions through one solution.